News | July 04, 2025
argenx advances clinical development of agonist antibody for myasthenic syndromes
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
mRNA-1010 demonstrated superior relative vaccine efficacy
ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
Subscribe To Our Newsletter & Stay Updated
